Literature DB >> 29136264

Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.

Sébastien Menzinger1, Gürkan Kaya, Enno Schmidt, Lionel Fontao, Emmanuel Laffitte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29136264     DOI： 10.2340/00015555-2845

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   4.437


× No keyword cloud information.
  7 in total

Review 1.  Immunoglobulin E-Mediated Autoimmunity.

Authors:  Marcus Maurer; Sabine Altrichter; Oliver Schmetzer; Jörg Scheffel; Martin K Church; Martin Metz
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

Review 2.  Role of the Pruritic Cytokine IL-31 in Autoimmune Skin Diseases.

Authors:  Bernhard F Gibbs; Nikolaos Patsinakidis; Ulrike Raap
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

Review 3.  Learning From Success and Failure: Biologics for Non-approved Skin Diseases.

Authors:  Reinhart Speeckaert; Jo Lambert; Nanja van Geel
Journal:  Front Immunol       Date:  2019-08-08       Impact factor: 7.561

4.  Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.

Authors:  S Morteza Seyed Jafari; Karolina Gadaldi; Laurence Feldmeyer; Nikhil Yawalkar; Luca Borradori; Christoph Schlapbach
Journal:  Front Immunol       Date:  2019-08-14       Impact factor: 7.561

5.  Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.

Authors:  Marina Alexandre; Gérôme Bohelay; Thomas Gille; Christelle Le Roux-Villet; Isaac Soued; Florence Morin; Frédéric Caux; Sabine Grootenboer-Mignot; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

6.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

Review 7.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.